Context: Cushing's syndrome (CS) is associated with symptoms that may impair health-related quality of life (HRQL).
T HE MAJORITY OF patients with Cushing's syndrome (CS) have physical and psychological symptoms that may lead to impaired health-related quality of life (HRQL) (1, 2) . Important functional impairments arising from hypercortisolism include muscle weakness, fracture, and cardiovascular events, which can adversely affect the survival and well-being of these patients (3) . Additional psychological consequences of hypercortisolism include depression (1), anxiety (4, 5) , and cognitive decrements (6) . Improved psychological functioning in CS has been observed after reversal of hypercortisolism (7, 8) . Short-term series have shown significant improvements occurring within the first year of treatment (9) . However, longer studies suggest that prolonged exposure to high levels of glucocorticoids may cause long-lasting deleterious effects (10 -12) .
Although the process of differential diagnosis and management of CS has been well validated (13) , outcomes in relation to quality of life have received less attention. Impaired HRQL in CS has recently been demonstrated using the standard short-form 36 (SF-36) health survey, which is an integrated measure of physical and psychological well-being (3, 10, 14, 15) . Previous studies were of relatively small groups of patients with Cushing's disease (CD) alone, with short duration of postoperative follow-up and in the absence of an age-and gender-matched control comparison.
We conducted a prospective study of HRQL using the SF-36 health survey in a cohort of patients with CD before and after transsphenoidal surgery (TSS). To characterize the impact on HRQL of successful treatment in CS, we also performed a cross-sectional analysis of HRQL in a cohort in long-term clinical remission, which included patients with ectopic, pituitary, and adrenal CS treated over a 25-yr period. The hypothesis was that we would observe improved HRQL after treatment and that HRQL would be greater with increasing duration of remission from hypercortisolism. We anticipated lower HRQL in patients with ectopic compared with adrenal-or pituitary-dependent CS due to associated comorbidity.
first author (J.R.L.) used an existing database of approximately 900 patients who had been enrolled in a range of protocols for investigation of CS. We identified 96 who had died since their inclusion in the protocol and excluded them from a mailing list sent to patients with confirmed CS. The survey was commenced in 1999, with two subsequent mailings in 2001 and 2004 to a total of 775 patients. Four hundred eighteen individuals returned 688 questionnaires; of these, 159 contributed two or more responses. Group 2 comprised a cross-sectional analysis of the most recent/latest questionnaire response from 343 subjects who were deemed to be in postoperative clinical remission. Seventy-five patients were excluded from this analysis, comprising eight patients who completed pretreatment responses alone, seven patients with insufficient follow-up data, and 60 individuals with possible/previously confirmed recurrence who are described below.
Quality of life
We used the SF-36R (version 2) for assessment of HRQL (16) . The SF-36 is a generic health survey that has been widely validated and used in an international context to evaluate self-reported domains of health status (16) . The SF-36 survey consists of a 36-item questionnaire that includes eight components of HRQL: physical functioning, role limitations due to physical health, bodily pain, general health, vitality, social functioning, role limitations due to emotional health, and mental health. These eight domains formed two broader health dimension scales: a physical component scale (PCS) and a mental component scale (MCS).
SF-36 scoring algorithms produce a standardized score for each of the two health dimensions by setting the general population mean at 50 Ϯ 10 (mean Ϯ 1 sd). To control for any difference in age and gender between the population norms and our sample, we compared our sample with age-and sex-matched U.S. population norms from 6742 subjects studied by Ware et al. (16) . To do this, we created a deviation score for each patient, calculated as the absolute difference between the individual's score and the appropriate age/gender norm. This score was then standardized to a z-score by dividing it by the sd for that age/gender norm. The resulting score, then, indicated for each individual how many sds the patient deviated from his/her own age/gender population norm. In our analyses, we present data using both the SF-36 standardized score as well as this age/gender-controlled deviation score.
In addition to the SF-36 quality of life dimensions, cognitive function was assessed with the Medical Outcomes Study cognitive functioning scale (17) . The Medical Outcomes Study quality of life assessment was the precursor to the SF-36; however, the cognitive functioning scale was omitted from the SF-36 in the interest of brevity. We elected to include the cognitive functioning scale, because this may be a particularly relevant dimension for this population.
Demographic variables and symptom checklist
The survey instrument included demographic data (age, gender, marital status, and highest grade of educational attainment), diagnosis, primary treatment, and subsequent treatments (surgery, medicine, or radiation) since discharge. The subjects were asked to indicate whether they had experienced a recurrence or were currently cured of CS and to indicate whether they were currently taking hydrocortisone, prednisone, dexamethasone, mitotane, or ketoconazole. All patients were requested to provide details of the most recent laboratory screening for objective assessment of remission status. Patients also were asked to indicate whether they were currently experiencing any of 42 items on a checklist containing signs and symptoms associated with CS.
Evaluation of long-term remission
The posttreatment cross-sectional analysis excluded patients with previously confirmed recurrence of CS as determined from our internal records (n ϭ 34) and patients who indicated that they were not cured (n ϭ 19). Patients with persistent hypercortisolism (n ϭ 2) or who required ketoconazole (n ϭ 4) or mitotane (n ϭ 1) treatment were excluded. These responses were cross-checked with our records and with returned results of biochemical screening for examination of remission status.
Statistical analysis
Descriptive statistics were calculated for continuous variables. Frequencies were generated for other variables. Significance was assumed at P Ͻ 0.05. All data including the SF-36 domains are expressed as the mean Ϯ sd, except where noted. 2 and Fisher's exact tests were used to examine differences in demographic variables. Only patients with both pre-and posttreatment responses were included in the intraindividual analysis for group 1. The mean and 95% confidence intervals (CIs) of z-scores for each group and domain were calculated. A mean z-score (effect size) less than 0.20 was considered clinically nonsignificant, a z-score in the range 0.2-0.5 was classified as small, a z-score in the range 0.5-0.8 as moderate, and a z-score greater than 0.8 as large (18, 19) . Spearman's rank test was used to examine correlations between SF-36 outcomes and continuous demographic variables.
An analysis of the effect of time from treatment on HRQL was conducted within group 2, which included serial observations from individual respondents. However, if a subject contributed more than one observation during a single 5-yr period, only the most recent observation in that time period was used. Data were analyzed using mixed model analysis of repeated measures, followed by post hoc testing for pairwise comparisons among the times from treatment, using Statistical Analysis System (SAS) version 8 software (SAS Institute, Inc., Cary, NC).
Logistic regression analysis was used to evaluate the relationship of the physical symptom score, time from treatment, glucocorticoid use, previous pituitary irradiation (XRT) and deviation of greater than 0.5 sd in PCS and MCS domains below the normative mean. Testing was performed using the statistical package for social science (SPSS version 12 for Windows, release 09.04, 2003, SPSS, Inc., Chicago, IL) and GraphPad PRISM version 4.00 for Windows (GraphPad, San Diego, CA; www.graphpad.com).
Results

Group 1: HRQL in CD before and after TSS
Patients with active CD (Table 1) had low PCS, MCS, and low individual SF-36 domain z-scores compared with ageand sex-matched controls (P Ͻ 0.05; Fig. 1 ). Pretreatment PCS and MCS scores improved from 32.6 Ϯ 10.5 and 38.8 Ϯ 12.5 to 45.8 Ϯ 12.7 and 50.5 Ϯ 9.6, respectively (P Ͻ 0.001), at postoperative follow-up (mean, 3.2 Ϯ 1.5; range, 0.7-5.4 yr; Table 2 ). All individual SF-36 domains improved after TSS (P Ͻ 0.05). We observed a significant improvement in cognitive function after treatment (56.2 Ϯ 25.8 vs. 73.2 Ϯ 29.4; P ϭ 0.02) Postoperatively, scores for bodily pain (P ϭ 0.5), vitality (P ϭ 0.4), social functioning (P ϭ 0.1), role limitations due to emotional health (P ϭ 0.6), general health (P ϭ 0.4), mental health (P ϭ 0.5), and the mental summary scores (P ϭ 0.8), improved to levels similar to U.S. population norms. In contrast, physical functioning (P ϭ 0.04), role limitations due to physical health (P ϭ 0.049) and physical summary (P ϭ 0.04) scores remained significantly below U.S. population norms.
Group 2: cross-sectional posttreatment survey of patients in clinical remission from CS
The characteristics of the 343 patients in remission from CS (CD, 89%; adrenal, 5%; ectopic, 6%) in the posttreatment cross-sectional sample were similar in terms of gender, education, and marital status to those in the posttreatment arm of group 1 (Table 1) . Compared with group 1, the patients were older by approximately 6 yr (P ϭ 0.06), a smaller proportion was treated by TSS alone (P ϭ 0.09), and they had a longer period of remission (P Ͻ 0.0001). The SF-36 domain results from the cross-sectional group and posttreatment arm of group 1 were not statistically different.
In the cross-sectional group, PCS scores were higher in men (P ϭ 0.02) and inversely associated with age (r ϭ Ϫ0.36; P Ͻ 0.001). Both PCS and MCS scores were independent of diagnostic category and educational status. Postoperatively at the longest follow-up point (11.8 Ϯ 4.9 yr; range, 0.7-25.8 yr), z-scores for SF-36 domains were low (P Ͻ 0.05) compared with age-and sex-matched population controls (Fig. 2) . Despite apparent clinical remission from CS, these patients had low PCS (45.7 Ϯ 0.7) and MCS (47.0 Ϯ 0.7) scores (mean Ϯ sem; P Ͻ 0.0001) compared with the general population controls (50 Ϯ 0.1). Corresponding z-scores for PCS and MCS were Ϫ0.4 Ϯ 1.2 and Ϫ0.3 Ϯ 1.2.
Subjective health rating and satisfaction scale among crosssectional analysis
Patients compared their current health to that before developing CS. Results from patients in the remission group were as follows: much better, 38%; somewhat better, 12%; about the same, 20%; somewhat worse, 20%; much worse, 7%; or missing, 3%. Similarly, when asked to rate their level of satisfaction with the outcome of treatment for CS, responses were: extremely satisfied, 57%; quite satisfied, 26%; moderately satisfied, 9%; slightly satisfied, 4%; not at all satisfied, 2%; or missing, 3%.
HRQL by time from treatment
We observed long-term higher PCS (P Ͻ 0.0001) and MCS (P Ͻ 0.01) scores in the cross-sectional analysis compared with the pretreatment arm of group 1 (Fig. 3 ). There were no significant changes in PCS or MCS scores in the posttreatment period with increasing time from treatment (P Ͼ 0.05). Table 3 demonstrates the prevalence of active symptoms in the cross-sectional series at the most recent follow-up. Group 1: Before and after TSS in CD; group 2: cross-sectional posttreatment analysis of patients in apparent remission from CS. Results are means (SD). ADX, Adrenalectomy; GED, General Educational Development; Rx, treatment.
Symptoms and relationship to SF-36 summary scores
a P Ͻ 0.0001 for comparison of demographic data of patients in the posttreatment arm of group 1 and those in the cross-sectional series.
Fatigue (41%), forgetfulness (35.7%), and trouble sleeping (33.3%) were the most common symptoms. The presence of any symptom was associated with lower PCS/MCS in all cases in which a significant difference was observed. The presence of symptoms measured using the total numerical score of positive symptoms was inversely related to SF-36 summary domains: PCS: r ϭ Ϫ0.5; P Ͻ 0.0001; and MCS: r ϭ Ϫ0.6; P Ͻ 0.0001.
Effect of glucocorticoids
Although patients requiring glucocorticoids after remission of CS had marginally lower physical summary z-scores (Ϫ0.5 Ϯ 1.3 vs. Ϫ0.3 Ϯ 1.2; P ϭ 0.05), the remainder of the SF-36 domains were similar (P Ͼ 0.05) compared with those who were glucocorticoid independent.
Predictors of HRQL
The use of glucocorticoids and previous pituitary XRT were not significantly associated with impaired PCS and/or MCS scores in a model that examined their relationship to z-score deviation of more than 0.5 sd below age-and sexmatched population means. Physical symptoms scores (defined in Table 3 ) were significantly associated with both impaired PCS and MCS. The odds ratio (95% CI) for impaired PCS was 14.4 (6.4 -32.7) and for MCS was 6.1 (2.9 -12.8) in those with six or more physical symptoms compared with those with none or one symptom. Increasing time from treatment was identified as a significant contributor to the observed variation in PCS scores, but not MCS scores. The odds ratios (95% CI) for impaired PCS was 0.4 (0.2-1.2), 0.36 (0.2-0.9), and 0.3 (0.1-0.6) for patients 0 -5, 5-10, and 10 -15 yr from treatment, respectively, compared with those who had been treated more than 15 yr previously. 
Differences between subjects in remission and those with a confirmed previous recurrence or persistent hypercortisolism at most recent mailing
We examined differences in SF-36 responses for those in apparent clinical remission compared with others who had been excluded from earlier analyses, as described above. PCS scores were lower among those who had a previous recurrence (37.6 Ϯ 12.2), those with persistent hypercortisolism (38.3 Ϯ 3.7), and those who believed they were not cured (34.2 Ϯ 11.8) compared with the remission group detailed above (by ANOVA, P Ͻ 0.0001). Similarly, when we examined MCS scores, patients with a previous recurrence (41.9 Ϯ 16.4), with persistent hypercortisolism (44.9 Ϯ 3.7), or who believed they were not cured (39.6 Ϯ 13.3) had lower scores than the remission group (P Ͻ 0.0001).
Discussion
The present series confirms that active CS is associated with impaired HRQL. The magnitude of difference compared with age-and sex-matched controls was large in all SF-36 domains, except for mental health and bodily pain, which were moderately impaired. The magnitude of these changes also was similar to previous reports that HRQL in active CS is significantly impaired compared with that in subjects with acromegaly, prolactinoma, or nonfunctioning tumors (14) .
Postoperative HRQL values within the first 3 yr of follow-up improved compared with pretreatment values. However, despite apparent clinical remission, when compared with the U.S. population, there was residual impairment primarily of physical scores, comprised of physical function- Column 2 demonstrates the percentage of patients who indicated the presence of active symptoms. a Symptoms that comprised physical symptoms score. Mean (ϮSD) norm-based PCS and MCS scores were calculated for each group with (ϩve) or without (Ϫve) symptoms and analyzed for significant differences using Student's unpaired t test;
ing, role limitations due to physical health, and PCS domains. In the remaining domains, no other differences were apparent at early postoperative follow-up compared with the general U.S. population. However, when compared with ageand gender-matched controls, HRQL remained impaired (see below). Our observations extend the early postoperative observations by Vance et al. (20) of HRQL in 20 patients with successfully treated CD. Although the baseline PCS scores in the present series were lower than those reported by that group at a mean of 13 months after surgery, the direction of change and postoperative values were similar. Lumachi et al. (21) also reported improved HRQL in 46 patients at 23 months after bilateral adrenalectomy for CD. All SF-36 components improved significantly, except for trends to improvement in the domain for emotional role and an increase in bodily pain, which were close to statistical significance (21) . Dorn et al. (9) reported the time course for improvements in psychopathology in 33 patients. From a baseline of 66% of affected adult patients before treatment, residual psychopathology was present in 53.6% at 3 months, 36% at 6 months, and 24.1% at 12 months of recovery from hypercortisolism (9) . Thus, the timing of survey administration during the early postoperative period may have influenced our results.
The present cross-sectional series demonstrated no significant differences in HRQL relating to treatment modality or between diagnostic categories, consistent with previous series (22) . However, the number of patients with nonpituitary disease was small, so that evaluation of a larger group might show a difference. It is also possible that the degree or duration of hypercortisolism influences HRQL. This study was not designed to answer that question.
Improved, but persistently impaired, HRQL may have significant social and economic consequences for the patient recovering from CS. In the current survey, although 57% of the patients were extremely satisfied with their treatment for CS, subjectively only 38% felt much better after treatment, 20% felt similar to before treatment, and 20% felt somewhat worse after treatment compared with before they developed CS. Hawn et al. (15) reported an objective decrease in HRQL in 11 patients, nine of whom reported that their health improved after adrenalectomy. Pikkarainen et al. (3) reported that despite improvements in HRQL after treatment in CS, the mean duration of postoperative sick leave was 3.8 months. After surgery, only about 81% were able to return to work, illustrating the potential socioeconomic burden during recovery from CS (3).
In the cross-sectional remission series, we observed moderate impairment of general health compared with age-and sex-matched controls over a mean time from treatment of almost 12 yr. All other domains, except for bodily pain, showed small residual impairments at long-term follow-up. Thus, as demonstrated by this and other reports, there is mounting evidence of persistent impairments in HRQL in subjects in long-term remission from CS (10, 12) . Others have reported impairments in HRQL at a mean of 29 months, 7.7 yr, and 13 yr after treatment (10).
We do not know exactly which factors contribute to impaired HRQL despite clinical remission at long-term followup. van Aken et al. (10) showed that hypopituitarism, which occurred in approximately half of the 58 subjects treated for CS, was an independent predictor of HRQL. Although we do not have biochemical data on the presence of hypopituitarism or GH deficiency in our cross-sectional series (see below), we did find small differences in SF-36 PCS scores for glucocorticoid users compared with age-and sex-matched population controls. These differences were not apparent in the logistic regression, suggesting that other factors are involved. Similarly, the absence of menses was associated with impaired PCS scores in women, and impotence was associated with lower PCS and MCS scores in men, suggesting that hypogonadism contributed to impaired HRQL. Using a logistic regression model that was controlled for age and gender, we did not find that previous pituitary XRT was a significant contributor, consistent with one recent small series that found similar HRQL in those who had never been or were treated with XRT (12) .
PCS scores were more likely to be below population norms in subjects 15 yr or more from treatment. These observations are in contrast to those of van Aken et al. (10) , who found no difference in HRQL arising from time interval since remission. Although that report was similar in terms of age, gender, and duration of remission, it only included patients with CD. Our series comprised a larger group of patients with a wider range of diagnoses and a smaller proportion who were glucocorticoid dependent. However, the exact reason for the differences between these series is unknown.
Other factors that may have contributed to persistent longterm impaired HRQL are irreversible effects of hypercortisolism on neurological function or physical conditioning (11) . Elevated cortisol levels in CS are associated with cognitive decrements and loss of brain volume (6) . Furthermore, the apparent decrease in hippocampal volume associated with functional impairments in cognition appeared to be only partially reversible upon correction of hypercortisolism (23, 24) . Similarly, deleterious effects on the cardiovascular system and metabolic parameters persist even after successful treatment of CS (25) . Unfortunately, in this series we do not have data on these and other comorbid conditions that may have influenced HRQL. However, previous studies using the SF-36 survey showed impaired HRQL in patients with ischemic heart disease and markers of the metabolic syndrome (25, 26) . It is possible that these and other factors may have contributed to the observed long-term impairment in HRQL in our series (25, 26) .
As would be expected, the presence of physical and mental symptoms was inversely related to PCS and MCS scores. We detected significantly higher SF-36 PCS scores in patients in apparent clinical remission compared with those with a definite previous recurrence and in those who indicated possible recurrence. In this respect the SF-36 health survey or the 42-item symptom checklist might have utility for screening patients for disease recurrence at postoperative follow up. We believe that the utility of these methods and their relationship to biochemical screening in postoperative surveillance merit prospective study.
This study has several limitations and biases. First, the paired pre-and posttreatment surveys included only 23 patients. Although these numbers are small relative to our larger cross-sectional group, they are similar to other pub-lished series (12, 20) . Second, because the National Institutes of Health serves as a worldwide referral center for management of CS, many patients resume posttreatment care with local endocrinology services and have not been uniformly reevaluated at the National Institutes of Health. Our determination of remission status relied primarily on self-report and limited biochemical data, with variable laboratory reference ranges and methodologies. Although no patient with definite recurrent hypercortisolism was included from the posttreatment series based on this information, we cannot exclude unrecognized recurrence in all.
Similarly, we could not quantify the prevalence of other factors that might impair HRQL. These include diminished GH reserve, present in about 20% in a previous series of patients treated for CS (12, 27) , as well as gonadal steroid deficiency or glucocorticoid-associated comorbidities leading to glucose intolerance, hypertension, and hyperlipidemia.
In conclusion, we have demonstrated impaired quality of life in CS that partially resolves after successful treatment. At long-term follow-up, despite apparent clinical remission, there is evidence of residual impairment of HRQL. Assessment of quality of life is an essential outcome measure in the postoperative period, which may have utility in the assessment of remission status at subsequent follow-up. Determination of modifiable factors that contribute to HRQL in this vulnerable population might help reduce the physical and psychosocial burden of disease.
